Sorry, you need to enable JavaScript to visit this website.

Indications & Dosing | DARZALEX® (daratumumab) & DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) HCP

More FDA-approved regimens for DARZALEX FASPRO® and DARZALEX® than any other monoclonal antibody in multiple myeloma1-4

Newly diagnosed
Transplant ineligible

DARZALEX® + Rd/

DARZALEX FASPRO® + Rd

View DRd dosing

DARZALEX® + VMP/

DARZALEX FASPRO® + VMP

View DVMP dosing

Transplant eligible

DARZALEX® + VTd/

DARZALEX FASPRO® + VTd

View DVTd dosing

Relapsed or refractory
After ≥1 prior therapy

DARZALEX® + Rd/

DARZALEX FASPRO® + Rd

View DRd dosing

DARZALEX® + Vd/

DARZALEX FASPRO® + Vd

View DVd dosing

DARZALEX FASPRO® + Pd

Prior line of therapy including lenalidomide and a proteasome inhibitor (PI).

View DPd dosing

After 1-3 prior lines of therapy

DARZALEX® + Kd/

DARZALEX FASPRO® + Kd

View DKd dosing

After ≥2 prior therapies

DARZALEX® + Pd

Prior therapies included lenalidomide and a PI.

View DPd dosing

After ≥3 prior therapies

DARZALEX® monotherapy/

DARZALEX FASPRO® monotherapy

Prior therapies included a PI and an immunomodulatory agent, or patients were double refractory to a PI and an immunomodulatory agent.

View monotherapy dosing

DKd=DARZALEX FASPRO®/DARZALEX® (D) + carfilzomib (K) + dexamethasone (d); DPd=DARZALEX FASPRO®/DARZALEX® (D) + pomalidomide (P) + dexamethasone (d); DRd=DARZALEX FASPRO®/DARZALEX® (D) + lenalidomide (R) + dexamethasone (d); DVd=DARZALEX FASPRO®/DARZALEX® (D) + bortezomib (V) + dexamethasone (d); DVMP=DARZALEX FASPRO®/DARZALEX® (D) + bortezomib (V) + melphalan (M) + prednisone (P); DVTd=DARZALEX FASPRO®/DARZALEX® (D) + bortezomib (V) + thalidomide (T) + dexamethasone (d); Kd=carfilzomib (K) + dexamethasone (d); Pd=pomalidomide (P) + dexamethasone (d); Rd=lenalidomide (R) + dexamethasone (d); Vd=bortezomib (V) + dexamethasone (d); VMP=bortezomib (V) + melphalan (M) + prednisone (P); VTd=bortezomib (V) + thalidomide (T) + dexamethasone (d).

Dosing schedules for DARZALEX FASPRO® and DARZALEX®

Once-monthly dosing over time—a key milestone for patients to reach in newly diagnosed, transplant-ineligible multiple myeloma1,2*

Starting at Cycle 7, patients will transition to approximately once-monthly dosing for DARZALEX FASPRO® or DARZALEX®

newly diagnosed drd dosing table
Continue DRd until disease progression or unacceptable toxicity

DRd=DARZALEX FASPRO®/DARZALEX® (D) + lenalidomide (R) + dexamethasone (d).

Cycle=28 days.

DARZALEX FASPRO® in combination with lenalidomide and dexamethasone (4-week cycle) has the same dosing schedule as DARZALEX® in combination with lenalidomide and dexamethasone.1,2‡

For more detailed information on dosing and administration, including management of infusion-related reactions (IRRs) and administration-related reactions (ARRs), please review the links below.

See DARZALEX FASPRO® administration details

Dosing and administration guide for DARZALEX FASPRO®

Download guide

See DARZALEX® administration details

Dosing and administration guide for DARZALEX®

Download guide

First dose of the every-2-week dosing schedule is given at Week 9. First dose of the every-4-week dosing schedule is given at Week 25.1,2

*See the Dosage and Administration section of the full Prescribing Information for more detail. When DARZALEX FASPRO® or DARZALEX® is administered as part of a combination therapy, see the Prescribing Information for dosage recommendations for the other drugs.

The option of splitting the first dose for DARZALEX® is not applicable to DARZALEX FASPRO®.1,2

 

Once-monthly dosing over time—a key milestone for patients to reach in newly diagnosed, transplant-ineligible multiple myeloma1,2*

Starting at Cycle 10, patients will transition to approximately once-monthly dosing for DARZALEX FASPRO® or DARZALEX®

Newly Diagnosed DVMP Dosing Table
Continue DVMP until disease progression or unacceptable toxicity

DVMP=DARZALEX FASPRO®/DARZALEX® (D) + bortezomib (V) + melphalan (M) + prednisone (P).

Cycle=42 days.

DARZALEX FASPRO® in combination with bortezomib + melphalan + prednisone (6-week cycle) has the same dosing schedule as DARZALEX® in combination with bortezomib + melphalan + prednisone.1,2‡

For more detailed information on dosing and administration, including management of infusion-related reactions (IRRs) and administration-related reactions (ARRs), please review the links below.

See DARZALEX FASPRO® administration details

Dosing and administration guide for DARZALEX FASPRO®

Download guide

See DARZALEX® administration details

Dosing and administration guide for DARZALEX®

Download guide

First dose of the every-3-week dosing schedule is given at Week 7. First dose of the every-4-week dosing schedule is given at Week 55.1,2

*See the Dosage and Administration section of the full Prescribing Information for more detail. When DARZALEX FASPRO® or DARZALEX® is administered as part of a combination therapy, see the Prescribing Information for dosage recommendations for the other drugs.

The option of splitting the first dose for DARZALEX® is not applicable to DARZALEX FASPRO®.1,2

Fixed-cycle dosing for patients in newly diagnosed, transplant-eligible multiple myeloma1,2*

Newly Diagnosed DVTd Dosing Table

DVTd=DARZALEX FASPRO®/DARZALEX® (D) + bortezomib (V) + thalidomide (T) + dexamethasone (d).

Cycle=28 days.

DARZALEX FASPRO® in combination with bortezomib + thalidomide + dexamethasone (4-week cycle) has the same dosing schedule as DARZALEX® in combination with bortezomib + thalidomide + dexamethasone.1,2‡

For more detailed information on dosing and administration, including management of infusion-related reactions (IRRs) and administration-related reactions (ARRs), please review the links below.

See DARZALEX FASPRO® administration details

Dosing and administration guide for DARZALEX FASPRO®

Download guide

See DARZALEX® administration details

Dosing and administration guide for DARZALEX®

Download guide

First dose of the every-2-week dosing schedule is given at Week 9. First dose of the every-2-week dosing schedule is given at Week 1 upon re-initiation of treatment following autologous stem cell transplant (ASCT).1,2

*See the Dosage and Administration section of the full Prescribing Information for more detail. When DARZALEX FASPRO® or DARZALEX® is administered as part of a combination therapy, see the Prescribing Information for dosage recommendations for the other drugs.

The option of splitting the first dose for DARZALEX® is not applicable to DARZALEX FASPRO®.1,2

Once-monthly dosing over time—a key milestone for patients to reach in relapsed or refractory multiple myeloma1,2*

Starting at Cycle 7, patients will transition to approximately once-monthly dosing for DARZALEX FASPRO® or DARZALEX®

Relapsed DRd Dosing Table
Continue DRd until disease progression or unacceptable toxicity

DRd=DARZALEX FASPRO®/DARZALEX® (D) + lenalidomide (R) + dexamethasone (d).

Cycle=28 days.

DARZALEX FASPRO® in combination with lenalidomide and dexamethasone (4-week cycle) has the same dosing schedule as DARZALEX® in combination with lenalidomide and dexamethasone.1,2‡

For more detailed information on dosing and administration, including management of infusion-related reactions (IRRs) and administration-related reactions (ARRs), please review the links below.

See DARZALEX FASPRO® administration details

Dosing and administration guide for DARZALEX FASPRO®

Download guide

See DARZALEX® administration details

Dosing and administration guide for DARZALEX®

Download guide

First dose of the every-2-week dosing schedule is given at Week 9. First dose of the every-4-week dosing schedule is given at Week 25.1,2

*See the Dosage and Administration section of the full Prescribing Information for more detail. When DARZALEX FASPRO® or DARZALEX® is administered as part of a combination therapy, see the Prescribing Information for dosage recommendations for the other drugs.

The option of splitting the first dose for DARZALEX® is not applicable to DARZALEX FASPRO®.1,2

Once-monthly dosing over time—a key milestone for patients to reach in relapsed or refractory multiple myeloma1,2*

Starting at Cycle 9, patients will transition to approximately once-monthly dosing for DARZALEX FASPRO® or DARZALEX®

Relapsed DVd Dosing Table
Continue DVd until disease progression or unacceptable toxicity

DVd=DARZALEX FASPRO®/DARZALEX® (D) + bortezomib (V) + dexamethasone (d).

Cycle=21 days.

DARZALEX FASPRO® in combination with bortezomib and dexamethasone (3-week cycle) has the same dosing schedule as DARZALEX® in combination with bortezomib and dexamethasone.1,2‡

For more detailed information on dosing and administration, including management of infusion-related reactions (IRRs) and administration-related reactions (ARRs), please review the links below.

See DARZALEX FASPRO® administration details

Dosing and administration guide for DARZALEX FASPRO®

Download guide

See DARZALEX® administration details

Dosing and administration guide for DARZALEX®

Download guide

First dose of the every-3-week dosing schedule is given at Week 10. First dose of the every-4-week dosing schedule is given at Week 25.1,2

*See the Dosage and Administration section of the full Prescribing Information for more detail. When DARZALEX FASPRO® or DARZALEX® is administered as part of a combination therapy, see the Prescribing Information for dosage recommendations for the other drugs.

The option of splitting the first dose for DARZALEX® is not applicable to DARZALEX FASPRO®.1,2

Once-monthly dosing over time—a key milestone for patients to reach in relapsed or refractory multiple myeloma1,2*

Starting at Cycle 7, patients will transition to approximately once-monthly dosing for DARZALEX FASPRO® or DARZALEX®

Relapsed DPd Dosing Table
Continue DPd until disease progression or unacceptable toxicity

DPd=DARZALEX FASPRO®/DARZALEX® (D) + pomalidomide (P) + dexamethasone (d).

Cycle=28 days.

DARZALEX FASPRO® in combination with pomalidomide and dexamethasone (4-week cycle) has the same dosing schedule as DARZALEX® in combination with pomalidomide and dexamethasone.1,2‡

For more detailed information on dosing and administration, including management of infusion-related reactions (IRRs) and administration-related reactions (ARRs), please review the links below.

See DARZALEX FASPRO® administration details

Dosing and administration guide for DARZALEX FASPRO®

Download guide

See DARZALEX® administration details

Dosing and administration guide for DARZALEX®

Download guide

First dose of the every-2-week dosing schedule is given at Week 9. First dose of the every-4-week dosing schedule is given at Week 25.1,2

*See the Dosage and Administration section of the full Prescribing Information for more detail. When DARZALEX FASPRO® or DARZALEX® is administered as part of a combination therapy, see the Prescribing Information for dosage recommendations for the other drugs.

The option of splitting the first dose for DARZALEX® is not applicable to DARZALEX FASPRO®.1,2

Once-monthly dosing over time—a key milestone for patients to reach in relapsed or refractory multiple myeloma1,2*

Starting at Cycle 7, patients will transition to approximately once-monthly dosing for DARZALEX FASPRO® or DARZALEX®

Relapsed DKd Dosing Table
Continue DKd until disease progression or unacceptable toxicity

DKd=DARZALEX FASPRO®/DARZALEX® (D) + carfilzomib (K) + dexamethasone (d).

Cycle=28 days.

DARZALEX FASPRO® in combination with carfilzomib and dexamethasone (4-week cycle) has the same dosing schedule as DARZALEX® in combination with carfilzomib and dexamethasone, with the exception of Week 1.1,2

For more detailed information on dosing and administration, including management of infusion-related reactions (IRRs) and administration-related reactions (ARRs), please review the links below.

See DARZALEX FASPRO® administration details

Dosing and administration guide for DARZALEX FASPRO®

Download guide

See DARZALEX® administration details

Dosing and administration guide for DARZALEX®

Download guide

First dose of the every-2-week dosing schedule is given at Week 9. First dose of the every-4-week dosing schedule is given at Week 25.1,2

*See the Dosage and Administration section of the full Prescribing Information for more detail. When DARZALEX FASPRO® or DARZALEX® is administered as part of a combination therapy, see the Prescribing Information for dosage recommendations for the other drugs.

Once-monthly dosing over time—a key milestone for patients to reach in relapsed or refractory multiple myeloma1,2*

Starting at Cycle 7, patients will transition to approximately once-monthly dosing for DARZALEX FASPRO® or DARZALEX®

Relapsed Monotherapy Dosing Table
Continue monotherapy treatment until disease progression or unacceptable toxicity

Cycle=28 days.

DARZALEX FASPRO® monotherapy (4-week cycle) has the same dosing schedule as DARZALEX® monotherapy.1,2 ‡

For more detailed information on dosing and administration, including management of infusion-related reactions (IRRs) and administration-related reactions (ARRs), please review the links below.

See DARZALEX FASPRO® administration details

Dosing and administration guide for DARZALEX FASPRO®

Download guide

See DARZALEX® administration details

Dosing and administration guide for DARZALEX®

Download guide

First dose of the every-2-week dosing schedule is given at Week 9. First dose of the every-4-week dosing schedule is given at Week 25.1,2

*See the Dosage and Administration section of the full Prescribing Information for more detail. When DARZALEX FASPRO® or DARZALEX® is administered as part of a combination therapy, see the Prescribing Information for dosage recommendations for the other drugs.

The option of splitting the first dose for DARZALEX® is not applicable to DARZALEX FASPRO®.1,2

National Comprehensive Cancer Network® (NCCN®) Guidelines recommendations for daratumumab-containing regimens

Review recommendations